Epogen and Procrit (epoetinalfa): Recall - Particulate Matter in Vials
by
FDAPosted
Fri 24 Sep 2010 4:48pm
[Posted 09/24/2010]
AUDIENCE: Risk Manager, Oncology, Nephrology
ISSUE: Amgen and FDA notified healthcare professionals that certain lots of Epogen and Procrit (Epoetinalfa) vials are being recalled as a precaution, because the vials may contain extremely thin glass flakes (lamellae) that are barely visible
Read on »
Amgen Initiates Voluntary Nationwide Recall Of Certain Lots Of Epogen® And Procrit® (EpoetinAlfa)
by
FDAPosted
Fri 24 Sep 2010 4:27pm
® (Epoetinalfa) vials are being voluntarily recalled from specialty distributors, wholesalers, pharmacies and healthcare providers as a precaution. The product that is being recalled... Biotech Products is the authorized distributor of PROCRIT in the United States.
About EPOGEN (Epoetinalfa)
EPOGEN is indicated for the treatment of anemia in patients
Read on »
Anemia in Kidney Failure and Dialysis Patients
by
juliusPosted
Mon 16 Nov 2009 10:02pm
that a patient could save through this option outweighs the dangers.
In my case I am taking EPO shots twice a week. I was taking 5000 units of Recormon (Erythropoetin or Epoetin Beta) during my earlier days of treatment. Last year I was shifted to Renogen (EpoetinAlfa). Both drugs treat kidney failure-related anemia. The shift was due to economical reasons
Read on »
New Warnings for Erythropoiesis-stimulating agents (ESAs)
by
Alan T.Posted
Fri 03 Oct 2008 11:31am
?
They are injectable drugs, genetically engineered forms of a protein, to boost the production of red blood cells.
In Malaysia, ESAs that are available include:
darbepoetin alfaepoetinalfa (Eprex)
epoetin beta (Recormon)
They are used for anemia in chronic kidney failure (epoietin alfa) and also cancer patients (darbepoetin alfa).
Anemia
Read on »
Anemia Drug May Raise Stroke Ris ...
by
Dr. Rubens D.Posted
Sat 31 Oct 2009 11:01pm
, the researchers noted.
In earlier studies, Aranesp and a similar drug, epoetinalfa, marketed as Procrit or Epogen, were linked to increased risk of death in cancer and stroke patients... and kidney disease without substantially improving their quality of life, a new study finds.
Darbepoetin alfa, marketed as Aranesp and known as an erythropoiesis-stimulating agent
Read on »
Read All About It: The Disease Management Journal
by
JaanSPosted
Tue 02 Dec 2008 3:08am
, Bookhart BK, Mody SH, Fournier A-A, Mallett D, Duh MS: The economic impact of pre-dialysis epoetinalfa on health care and work loss costs in chronic kidney disease: an employers' perspective.
Patients who got "epo" in the months prior to starting dialysis subsequently had lower claims expense compared to those who didn't. The article's authors included
Read on »
Late-breaking data to be present ...
by
Dr. Rubens D.Posted
Sun 07 Dec 2008 10:54am
, a meta-analysis was conducted of 13,933 patients with cancer enrolled in 53 randomized, controlled clinical trials comparing epoetinalfa, epoetin beta, and darbepoetin alfa plus... with sickle cell disease.
Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis
Read on »